From €1336EUR$1,500USD£1,165GBP
- Report
- November 2024
- 150 Pages
Global
From €4319EUR$4,850USD£3,766GBP
- Report
- November 2025
- 36 Pages
Canada
From €4448EUR$4,995USD£3,879GBP
From €4319EUR$4,850USD£3,766GBP
- Report
- October 2025
- 100 Pages
Saudi Arabia
From €4319EUR$4,850USD£3,766GBP
From €4319EUR$4,850USD£3,766GBP
- Report
- October 2025
- 81 Pages
France
From €4319EUR$4,850USD£3,766GBP
- Report
- November 2025
- 160 Pages
Global
From €2990EUR$3,358USD£2,607GBP
€3518EUR$3,950USD£3,067GBP
- Report
- February 2026
- 95 Pages
Global
From €3500EUR$4,210USD£3,159GBP
- Report
- August 2025
- 116 Pages
Global
From €3500EUR$4,210USD£3,159GBP
- Report
- November 2023
- 98 Pages
Global
From €1336EUR$1,500USD£1,165GBP
The Real World Evidence (RWE) market within the context of E-Healthcare is a rapidly growing sector. It is a form of evidence-based medicine that uses data from real-world sources such as patient records, claims data, and observational studies to inform healthcare decisions. RWE can be used to assess the safety and effectiveness of treatments, identify new indications for existing treatments, and inform healthcare policy. It can also be used to assess the cost-effectiveness of treatments and to identify potential areas of improvement in healthcare delivery.
RWE is increasingly being used by healthcare providers, payers, and pharmaceutical companies to inform their decisions. It is also being used by researchers to gain insights into the effectiveness of treatments and to identify potential areas of improvement in healthcare delivery.
Some companies in the RWE market include IBM Watson Health, Optum, Flatiron Health, and Evidation Health. Show Less Read more
